key: cord-1004953-o3m7040j
authors: Draper, Bridget Louise; Htay, Hla; Pedrana, Alisa; Yee, Win Lei; Howell, Jessica; Pyone Kyi, Khin; Naing, Win; Sanda Aung, Khin; Markby, Jessica; Easterbrook, Philippa; Bowring, Anna; Aung, Win; Sein, Yi Yi; Nwe, Nwe; Myint, Kyi Thar; Shilton, Sonjelle; Hellard, Margaret
title: Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar
date: 2021-07-10
journal: Liver Int
DOI: 10.1111/liv.14983
sha: c610d0c0502ddddc18ad91e79bd6fe053473b056
doc_id: 1004953
cord_uid: o3m7040j

BACKGROUND: With the advent of low‐cost generic direct‐acting antivirals (DAA), hepatitis C (HCV) elimination is now achievable even in low‐/middle‐income settings. We assessed the feasibility and effectiveness of a simplified clinical pathway using point‐of‐care diagnostic testing and non‐specialist‐led care in a decentralized, community‐based setting. METHODS: This feasibility study was conducted at two sites in Yangon, Myanmar: one for people who inject drugs (PWID), and the other for people with liver disease. Participants underwent on‐site rapid anti‐HCV testing and HCV RNA testing using GeneXpert((R)). General practitioners determined whether participants started DAA therapy immediately or required specialist evaluation. Primary outcome measures were progression through the HCV care cascade, including uptake of RNA testing and treatment, and treatment outcomes. FINDINGS: All 633 participants underwent anti‐HCV testing; 606 (96%) were anti‐HCV positive and had HCV RNA testing. Of 606 tested, 535 (88%) were RNA positive and had pre‐treatment assessments; 30 (6%) completed specialist evaluation. Of 535 RNA positive participants, 489 (91%) were eligible to initiate DAAs, 477 (98%) completed DAA therapy and 421 achieved SVR12 (92%; 421/456). Outcomes were similar by site: PWID site: 91% [146/161], and liver disease site: 93% [275/295]). Compensated cirrhotic patients were treated in the community; they achieved an SVR12 of 83% (19/23). Median time from RNA test to DAA initiation was 3 days (IQR 2‐5). CONCLUSIONS: Delivering a simplified, non‐specialist‐led HCV treatment pathway in a decentralized community setting was feasible in Yangon, Myanmar; retention in care and treatment success rates were very high. This care model could be integral in scaling up HCV services in Myanmar and other low‐ and middle‐income settings.

An estimated 71 million people live with hepatitis C (HCV) infection, 75% in low-and middle-income countries (LMICs). 1 The World

Health Organization (WHO) set the goal of eliminating HCV as a public health threat by 2030, 2 but few countries are on track. 3 

LMICs, limited specialized workforces and the cost of diagnostics and treatment are major barriers to elimination. 4 To achieve elimination targets, considerable investment is required 5, 6 and treatment access must be scaled up via decentralized, simplified clinical pathways utilizing non-specialist physicians. 7 Direct-acting antivirals (DAAs)-well-tolerated, short-duration (typically 8-12 weeks), all-oral regimens, effective for all virus genotypes-have revolutionized the global response to HCV. 8 Clinical trial data of most DAA regimens demonstrate sustained virological response at 12 weeks post-treatment (SVR12) rates of over 95%, with many close to 100%. 9 Their simplicity and low toxicity profile 9 allow prescribing by general practitioners (GPs-aka primary care physicians), facilitating treatment of most HCV patients in the community, with complex cases referred for specialist review. 8 In many settings, the diagnostic pathway requires multiple blood draws and appointments, with substantial loss to follow-up at each step. 10 Rapid point-of-care (PoC) tests now enable diagnosis of active infection within one encounter, without centralized laboratory facilities.

These advances allow implementation of a 'one-stop-shop' model of testing and treatment in decentralized health facilities, with task shifting from specialists to GPs, supported by WHO guidelines. 8 Treatment outcomes of non-specialist-led HCV clinical pathways are non-inferior to those in specialist-led care. 11, 12 Moreover, models of care in Egypt, Pakistan, Iran and Australia providing onsite rapid anti-HCV testing, phlebotomy (including on-site PoC RNA testing or sample referral) and treatment prescription have demonstrated high retention [13] [14] [15] [16] and treatment uptake. [13] [14] [15] Evidence from a Cambodian GP-led programme suggest that iterative simplification of HCV clinical pathways does not reduce safety or effectiveness of care, 17 but does reduce cost per cure. 18 'One-stop-shop' models can deliver acceptable, convenient and accessible service in the community at reduced cost. [13] [14] [15] [16] [17] [18] [19] [20] Myanmar is a South-East Asian LMIC with 53 million people, 21 an estimated 1.4 million (2.7%) of whom are anti-HCV positive. 22 Before 2000, when blood donation screening was improved, 23 most were progression through the HCV care cascade, including uptake of RNA testing and treatment, and treatment outcomes.

Findings: All 633 participants underwent anti-HCV testing; 606 (96%) were anti-HCV positive and had HCV RNA testing. Of 606 tested, 535 (88%) were RNA positive and had pre-treatment assessments; 30 

Our methods are described briefly below, and in detail elsewhere. 28 The study was conducted at two study sites in Yangon, 

Interested participants were screened using the pre-enrolment criteria, 28 and eligible participants signed informed consent forms. GPs took short medical histories and referred them to on-site laboratory technicians ( Figure 1 ). Technicians took 10-11 mL of blood, then conducted the WHO prequalified PoC rapid diagnostic test (RDT) for anti-HCV (SD BIOLINE). Following a reactive RDT result, HCV on-site RNA testing involved the WHO prequalified Xpert hepatitis C VL assay on the GeneXpert® System (Cepheid). All HCV-RNA-positive participants then had HIV and HBV RDTs, liver function tests, renal function tests and a full blood examination. RDTs were conducted on-site and all other blood tests at a private laboratory nearby, with samples collected from study sites daily and results emailed within 24 hours.

The aspartate aminotransferase to platelet ratio index (APRI) score was calculated to assess cirrhosis and inform length of treatment (12 or 24 weeks). The APRI score is calculated as:

Participants were asked to return for review of pre-treatment assessments; GPs performed a clinical assessment for physical signs of decompensated cirrhosis, and determined whether the participant required hepatologist or other specialist evaluation. Participants with (i) ALT or AST >200 U/L, (ii) bilirubin above 1.14 mg/dL, (iii) 

Our data collection procedures have been described previously. 28 In brief, we collected clinical case report forms and participants completed behavioural and acceptability questionnaires. GPs completed case report forms using an electronic database (OpenMRS) at every clinical visit. Participants completed questionnaires in Burmese (the primary language spoken in Yangon) through REDCap, with optional assistance from the study nurse. We will undertake (and publish separately) an in-depth feasibility and scalability assessment of the model through document review and analysis of key informant interviews, covering factors contributing to successful implementation and key requirements for scalability. 

The cascade of care for the 633 study participants is presented in Figure 2 . Progression through the care cascade, including primary and secondary outcome measures, is presented by site in Table 2 . Of the participants screened for anti-HCV, 96% were antibody positive; of these, 100% had RNA testing and 88% were positive ( Figure 2 ); anti-HCV and HCV RNA positivity were similar by site (Table 2) .

Among the RNA-positive participants, 86% (459/535) were eligible to initiate DAA therapy by the GP directly and 6% (30/535) required specialist evaluation first ( Figure 2) . A higher proportion underwent specialist evaluation at the BI site ( Table 2 ). The most common reason for specialist review was elevated liver function test results (Table 3 ). In all, 26 participants were reviewed by a hepatologist, and four by other specialists; all but one were eligible for treatment.

In total, 489/535 participants with current HCV were eligible for treatment; 488 started treatment and were managed by GPs in community-based settings. Proportions initiating DAA treatment differed by site due to the proportion eligible (Table 2) . Forty-six RNA-positive participants were ineligible to commence DAA therapy, mostly due to HIV or HBV co-infection ( Figure 2 ). Those ineligible for DAA therapy in the study were referred to other treatment programmes.

Of 488 DAA initiators, 483 (99%) received all monthly treatment refills and 477 (98%) completed treatment per protocol (Figure 2 ).

Per protocol treatment completion did not differ significantly by site (Table 2) , and only five participants discontinued treatment Prefer not to answer' responses included in denominator: a 5 responded 'prefer not to answer'. b 1 responded 'prefer not to answer'. c 13 responded 'prefer not to answer'. d 28 had no mode of acquisition selected and were excluded from the denominator. e Fisher's exact test used for variables where there was a cell n < 5.

( Figure 2 ). Forty-seven participants reported missing at least one dose, but 39 (83%) missed fewer than seven doses. Most participants (91%) reported no side effects at monitoring visits.

Of 488 who commenced treatment, 421 (86%) achieved SVR12 using ITT analysis, including 12 patients with detectable but unquantifiable HCV VL (<10 IU/L) at SVR12 who had confirmed clearance at SVR24. Similarly, high rates of SVR12 were achieved in ITT analysis across both sites (Table 2 ). mITT analysis of SVR12, restricted to treatment outcomes among those tested, showed high rates of SVR12 at both sites (Table 2 ).

Clinical characteristics of the 488 treatment initiators are presented in Table 4 , disaggregated by cirrhosis status, defined as APRI score below or above cut-off of 2.0 (or 1.5 after 6 September 2019).

Most participants with cirrhosis were from the MLF Clinic (n = 19, 76%). Compared to non-cirrhotic participants, those with cirrhosis were more likely to have AST and ALT levels outside the normal range (100% vs 34%, 68% vs 26%, respectively), and to have lower platelet counts consistent with portal hypertension (84% vs 8%).

Treatment outcomes in non-cirrhotic and cirrhotic participants were 87% vs 76% (P = .126, ITT) and 93% vs 83% (P = .090, mITT) when restricted to those tested, with a (non-significantly) lower proportion of cirrhotic participants achieving SVR12. Treatment outcomes were similar when restricted to those who completed treatment per protocol (non-cirrhotic: 88% vs cirrhotic: 91%, P = .705).

Of those who did not achieve SVR12 (n = 35), five reported missing doses: two missed fewer than seven doses and three seven or more doses. Of those who did not achieve SVR12, 12 (34%) participants reported injecting drug use in the past 6 months at SVR12, therefore were possibly re-infected with hepatitis C. Dried blood spot samples were taken at screening and at SVR12 for further testing to distinguish reinfection from treatment failure. (Testing for reinfection was delayed due to COVID-19 restrictions, so these findings will be reported in a subsequent paper.)

Most participants (n = 444, 91%) required two visits before initiating treatment and receiving their first month of DAA medication: one visit for HCV testing (RDT and RNA testing) and one visit for review of pre-treatment investigations and treatment initiation. RDT and RNA tests were conducted on the same day for 587 participants (97%).

There was a statistically significant difference between median time for those not requiring specialist review ( 

Implementing a simplified one-stop-shop clinical pathway, using PoC diagnostic testing and GP-initiated DAA therapy, in a decentralized, community-based setting, was feasible in Myanmar. It was also feasible for GPs to manage compensated cirrhotic patients in the community setting and to facilitate timely access to specialist review, including hepatologists and other relevant specialists, through a 'hub-and-spoke' approach where required.

Retention in care was high throughout our care cascade.

Similar simplified, decentralized models of care have been implemented elsewhere, 13, 14, 17, [29] [30] [31] [32] but few are 'one-stop-shops' with non-specialist-led care in the community. 20 Retention in care was slightly higher in our study than in a similar care model implemented in Egypt, where linkage and treatment uptake in the early cascade was over 90%. 13 The Egyptian model involved specialistled care, not GP-led care, and was implemented over one to three days, with same-day testing and treating implemented by the outreach clinical team, and did not report SVR12 uptake and rate. Retention in care was equally high for PWID in our study.

Many studies of HCV models of care focus on lowering barriers to care and reducing attrition among PWID, but most have been conducted in middle-and high-income settings. 19 Barriers to care for PWID include the multi-step process of accessing treatment and previous experiences of discrimination in healthcare. 33 High retention in care among PWID in our study, most of whom were current injectors, points to the benefit of convenient care; the study site was near a methadone dispensary and the study site provided needle and syringe exchange. This care model appeared convenient for participants at both sites, because they only attended one community-based location for care, and the simplified pathway reduced visit frequency to two in most instances and the time from screening test to starting treatment to a median of 3 days. Time to start treatment was generally shorter than in other studies, where time varied from zero days (same-day test and treat) 13 to 100, 14 depending on the clinical pathway and model of care implemented. We will explore the acceptability of this model of care in forthcoming qualitative work.

Most participants were managed by GPs, without referral for specialist evaluation, including participants currently injecting drugs and participants with cirrhosis. The mITT SVR12 rates among those tested were high at 92%, and importantly, cure rates were no worse among PWID nor those with cirrhosis. The observed cure rates were similar to those reported in early clinical trials using sofosbuvir and daclatasvir (sof/dac) regimens: the ALLY-3 Phase III clinical trial of a sof/dac regimen for genotype 3 patients reported 90% SVR12 achievement among HCV/HIV co-infected treatment-naïve patients. 34 Our treatment outcomes were also similar to those of an F I G U R E 2 Clinical pathway progression. Participant progression through clinical pathway, including ineligible participants and those lost to follow-up observational study in Myanmar of sof/dac (+/− ribavirin), treating mostly genotypes 3 and 6. 35 In our study, adherence to DAA therapy was very high; only 9.6% of participants reported missing any doses, and the majority of them missing fewer than seven doses. Adequate adherence to DAA therapy has often been cited among GPs and specialist physicians as a concern for treating people who are actively injecting drugs for their chronic HCV infection. 36 However, results from our study, and from pooled analyses of adherence and SVR rates, 37,38 including among people who actively inject drugs, demonstrate that adherence was not of particular concern among this group who consistently report high adherence and SVR rates. Importantly, we found similarly good treatment outcomes in both cirrhotic (83%) and non-cirrhotic (93%) groups, when restricted to those who were assessed for SVR12 ( P = .090, mITT). This is consistent with results from a study of outcomes among genotype 3 cirrhotic patients treated with sof/dac (+/− ribavirin) reporting mITT analysis where 80% of those with cirrhosis achieving SVR12. 39 Our findings suggest that treating cirrhotic patients in the community is safe and effective, with few participants not achieving SVR12 and no serious adverse events related to DAA therapy. This is consistent with literature from simplified model of care utilizing sof/dac implemented in Cambodia where those with cirrhosis were safely managed by GPs and 94.9% achieved a cure. 17 Therefore, this care model and clinical pathway will not result in more referrals to specialists to manage treatment failures, further supporting the effectiveness of task-shifting of care and treatment from tertiary-based specialists to community-based non-specialists, using a 'hub-and-spoke' referral model. These results support the treatment of all patients without cirrhosis, including PWID, using simplified clinical pathways in community-based settings, and demonstrate the potential for treatment as prevention for PWID, with 91% achieving SVR12.

Several limitations to the generalizability of these study findings need to be considered before wider implementation, including characteristics of the participant group and the project setting.

Testing and treatment were provided at no cost to the participants, which may have encouraged retention in care in a setting TA B L E 2 Care cascade outcomes, by clinic and total Per protocol analysis = analysis of SVR12 achievement, among those who completed treatment.

ITT analysis = analysis of SVR12 achievement among all those initiated on DAA treatment.

mITT analysis = analysis of SVR12 achievement, only among those tested for SVR12. a Primary outcome measures.

b Secondary outcome measures.

Elevated liver function test (ALT, AST, bilirubin) 22

Low platelet count 1

Referral for chest X-ray to exclude tuberculosis/ pneumonia Normal ranges for sex, as per laboratory standards: AST normal cut-off: <59 U/L for male, <36 U/L for female; ALT normal cut-off: <72 U/L for male, <52 U/L for female; Bilirubin normal cut-off: >1.14 mg/dL; eGFR normal cut-off: >90 mL/min/1.73 m 2 ; Albumin cut-off: <3.5 g/dL; Creatinine normal cut-off: 1.2 mg/dL.

Per protocol analysis = analysis of SVR12 achievement, among those who completed treatment.

ITT analysis = analysis of SVR12 achievement among all those initiated on DAA treatment.

mITT analysis = analysis of SVR12 achievement, only among those tested for SVR12. be considered, particularly for patients who cannot attend frequently due to employment or caring commitments, or clinic location.

More participants (88%) were RNA positive than is commonly reported (75%) among people with HCV. 40 

This study demonstrates the feasibility and effectiveness of a simplified HCV treatment pathway implemented in a decentralized, community-based setting, utilizing PoC diagnostics and non-specialist led care. Such models are promoted by WHO and other global organizations, recognizing the importance of integrated and fully decentralized simplified care models and task-shifting to non-specialists as good practice principles. Our findings support Myanmar's national hepatitis C guidelines and the development of formal recommendations from WHO on simplified service delivery to support the expansion of HCV testing and treatment in other LMICs. 

The anonymized dataset will be held by the chief investigator.

The authors acknowledge the contributions of study participants, the clinical team, the specialist hepatologists from Yangon public hospitals, our database developers, and the support of the Myanmar National Hepatitis Control Program for the successful implementation of the study.

Gilead Sciences and Abbvie for unrelated work. AP has received investigator-initiated grant funding from Gilead Sciences, MSD and Abbvie and speaker fees from Gilead Sciences for unrelated work. 

All patients were taken through the informed consent process in Burmese, were provided with a written information sheet and signed an approved written informed consent form.

Bridget Louise Draper https://orcid.org/0000-0003-2624-2510

World Health Organization (WHO)

Global Health sector strategy on viral hepatitis

Center for Disease Analysis Foundation. Polaris observatory-HCV elimination maps

Progress report on access to hepatitis C treatment: focus on overcoming barriers in low-and middle-income countries

Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30

Innovative strategies for the elimination of viral hepatitis at a national level: a country case series

Global hepatitis C elimination: an investment framework

Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

Hepatitis C pointof-care diagnostics: in search of a single visit diagnosis

Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis

A same day "test and treat" model for chronic HCV and HBV infection: results from two community-based pilot studies in Egypt

From risk to care: the hepatitis C screening and diagnostic cascade in a primary health care clinic in Karachi, Pakistan-a cohort study

An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study

Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study

High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in

Cost and costeffectiveness of a simplified treatment model with directacting antivirals for chronic hepatitis C in Cambodia

We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade

A systematic review and meta-analysis of community and primarycare-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

Myanmar country profile

Sero-prevalence of Hepatitis B and C Viral Infections in Myanmar: National and Regional Survey in 2015

Myanmar Integrated Biological and Behavioural Survey and Population Size Estimates among People Who Inject Drugs (PWID)

hepat itis-simpl ified -treat ment-guide lines -for-hepat itis-c-infec tion 26. Ministry of Health and Sports Myanmar. Myanmar national simplified treatment guidelines for hepatitis C infection-second edition

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Decentralized, communitybased hepatitis C point-of-care testing and direct-acting antiviral treatment for people who inject drugs and the general population in Myanmar: protocol for a feasibility study

Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting

Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvirsofosbuvir (SHARED): a single-arm trial

Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial

Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?

Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in Myanmar

Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies

Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

The natural history of hepatitis C virus (HCV) infection

Reducing read time of point-of-care test does not affect detection of hepatitis C virus and reduces need for reflex RNA

Outcomes of the CT2 study: A 'one-stop-shop' for communitybased hepatitis C testing and treatment in Yangon